Related Experiment Video
Updated: Aug 18, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
ATM activation in normal human tissues and testicular cancer
Jirina Bartkova1, Christopher J Bakkenist, Ewa Rajpert-De Meyts
1Institute of Cancer Biology and Centre for Genotoxic Stress Research, Danish Cancer Society, Copenhagen, Denmark.
Abstract:
The ATM kinase is a tumor suppressor and key regulator of biological responses to DNA damage. Cultured cells respond to genotoxic insults that induce DNA double-strand breaks by prompt activation of ATM through its autophosphorylation on serine 1981. However, whether ATM-S1981 becomes phosphorylated in vivo, for example during physiological processes that generate DSBs, is unknown. Here we produced phospho-specific monoclonal antibodies against S1981-phosphorylated ATM (pS-ATM), and applied them to immunohistochemical analyses of a wide range of normal human tissues and testicular tumors. Our data show that regardless of proliferation and differentiation, most human tissues contain only the S1981-nonphosphorylated, inactive form of ATM. In contrast, nuclear staining for pS-ATM was detected in subsets of bone-marrow lymphocytes and primary spermatocytes in the adult testes, cell types in which DSBs are generated during physiological V(D)J recombination and meiotic recombination, respectively. Among testicular germ-cell tumors, an aberrant constitutive pS-ATM was observed especially in embryonal carcinomas, less in seminomas, and only modestly in teratomas and the pre-invasive carcinoma-in-situ stage. Compared with pS-ATM, phosphorylated histone H2AX (gammaH2AX), another DNA damage marker and ATM substrate, was detected in a higher proportion of cancer cells, and also in normal fetal gonocytes, and a wider range of adult spermatocyte differentiation stages. Collectively, our results strongly support the physiological relevance of the recently proposed model of ATM autoactivation, and provide further evidence for constitutive activation of the DNA damage machinery during cancer development. The new tools characterized here should facilitate monitoring of ATM activation in clinical specimens, and help develop future treatment strategies.
Insights
ATM kinase (serine 1981 phosphorylation) activation occurs in vivo during DNA double-strand break (DSB) repair in specific human tissues. Aberrant ATM activation is observed in testicular cancers, supporting its role in tumor development.
Area of Science:
- Molecular Biology
- Cellular Biology
- Oncology
Background:
- ATM kinase is a crucial tumor suppressor regulating DNA damage responses.
- ATM activation involves autophosphorylation on serine 1981, but its in vivo relevance is unclear.
- Genotoxic insults in cultured cells trigger ATM activation via double-strand breaks (DSBs).
Purpose of the Study:
- To investigate the in vivo phosphorylation of ATM on serine 1981.
- To analyze ATM activation in normal human tissues and testicular tumors.
- To validate the physiological relevance of ATM autoactivation models.
Main Methods:
- Development of phospho-specific monoclonal antibodies against S1981-phosphorylated ATM (pS-ATM).
- Immunohistochemical analysis of normal human tissues and testicular germ-cell tumors.
- Comparison with gammaH2AX as a DNA damage marker.
Main Results:
- Most normal tissues show inactive, nonphosphorylated ATM.
- Active pS-ATM detected in bone marrow lymphocytes and spermatocytes, sites of V(D)J and meiotic recombination.
- Constitutive pS-ATM observed in embryonal carcinomas, seminomas, and teratomas, with varying levels.
- GammaH2AX detected more broadly than pS-ATM in cancer cells and normal tissues.
Conclusions:
- The study supports the physiological relevance of ATM autoactivation during DNA double-strand break repair.
- Aberrant ATM activation is evident in testicular cancers, suggesting a role in tumorigenesis.
- The developed pS-ATM antibodies are valuable tools for monitoring ATM activation in clinical settings and developing therapies.

